Editor
Crown Laboratories, owner of Blue Lizard sunscreen and the premium skincare line Strivectin, announced on Monday a merger with medical aesthetics firm Revance. Revance, which has been listed on the Nasdaq since 2014, makes injectable treatments such as plumping hyaluronic acid fillers and Daxxify, a Botox alternative.
Under the agreement, Crown will make a tender offer to acquire all of Revance’s outstanding common stock shares for $6.66 in…
